| Literature DB >> 33414425 |
SunYoung Park1,2, Ji-Hwan Park3, Un-Beom Kang4, Seong-Kyoon Choi5,6, Ahmed Elfadl1, H M Arif Ullah1, Myung-Jin Chung1, Ji-Yoon Son1, Hyun Ho Yun1, Jae-Min Park1, Jae-Hyuk Yim1, Seung-Jun Jung1, Sang-Hyup Kim1, Young-Chul Choi7, Dae-Seong Kim8, Jin-Hong Shin8, Jin-Sung Park9, Keun Hur10, Sang-Han Lee11, Eun-Joo Lee1, Daehee Hwang12, Kyu-Shik Jeong13,14.
Abstract
Among the three isoforms encoded by Rtn4, Nogo-A has been intensely investigated as a central nervous system inhibitor. Although Nogo-A expression is increased in muscles of patients with amyotrophic lateral sclerosis, its role in muscle homeostasis and regeneration is not well elucidated. In this study, we discovered a significant increase in Nogo-A expression in various muscle-related pathological conditions. Nogo-/- mice displayed dystrophic muscle structure, dysregulated muscle regeneration following injury, and altered gene expression involving lipid storage and muscle cell differentiation. We hypothesized that increased Nogo-A levels might regulate muscle regeneration. Differentiating myoblasts exhibited Nogo-A upregulation and silencing Nogo-A abrogated myoblast differentiation. Nogo-A interacted with filamin-C, suggesting a role for Nogo-A in cytoskeletal arrangement during myogenesis. In conclusion, Nogo-A maintains muscle homeostasis and integrity, and pathologically altered Nogo-A expression mediates muscle regeneration, suggesting Nogo-A as a novel target for the treatment of myopathies in clinical settings.Entities:
Year: 2021 PMID: 33414425 PMCID: PMC7791112 DOI: 10.1038/s41420-020-00384-x
Source DB: PubMed Journal: Cell Death Discov ISSN: 2058-7716